Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, announced terms for its IPO on Friday. The Basking Ridge, NJ-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Regado Biosciences would command a market value of $219 million. Regado Biosciences, which was founded in 2001, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on March 1, 2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
